First Actos ruling the shape of things to come?
This article was originally published in Scrip
Executive Summary
In what could be seen as either a worrying precedent or significant patient victory, a US court has awarded a total of $6.5 million in compensatory damages to a plaintiff and his wife in the first case to come to trial on the bladder cancer risks of Takeda's former blockbuster diabetes drug Actos (pioglitazone).